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Abstract A computer-based differential display tool named
HsAnalyst has been developed and successfully used for the
comparison of expression patterns in a set of tumours versus a set
of normal tissues. A list of EST clusters highly represented in
tumours and rarely observed in normal tissues has been developed
as a resulting output file of the program. These differentially
expressed EST clusters (genes) can be useful for developing new
tumour markers and prognostic indicators for a wide set of
human malignancies. Tumour-specific protein-coding genes may
be considered a manifestation of tumour-specific gene
expression. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
Key words: Computer-based di¡erential display; Cancer;
Gene expression
1. Introduction
Comparing patterns of gene expression in di¡erent cell lines
and tissues has important implications for various biological
problems. The search for human genes speci¢cally expressed
in di¡erent tumours is one of the major challenges for modern
tumour biology. A number of experimental methods are de-
signed for tumour-speci¢c gene search. Most of them are
based on time-consuming and expensive experimental proto-
cols (numerous modi¢cations of the di¡erential display ap-
proach, cDNA microarrays, serial analysis of gene expression)
[1,2].
The total number of ESTs in publicly available databases
(s 2U106) exceeds by approximately two orders of magni-
tude the total number of di¡erent transcripts that can be
deduced from the number of human genes (2.5^4U104)
[3,4]. This provides a strong basis for the development of
computer-based procedures for the subtraction of di¡erent
EST pools instead of traditional experimental approaches
used to compare expression pro¢les. An attractive method
of in silico search for tumour-speci¢c genes would be a ‘com-
puter-based di¡erential display’ (CDD), an analogue of exper-
imental di¡erential displays. The principle of CDD is to com-
pare expression patterns in a particular tissue versus any other
tissue source. This comparison is based on sequence databases
publicly available in the World Wide Web. As an example of
successful implementation of CDD the search for prostate-
speci¢c genes performed by Vasmatzis et al. [12] can be con-
sidered. A similar approach was also used for the search of
di¡erentially or ectopically expressed genes in particular tu-
mour types in comparison to the corresponding normal tissue
[13]. We tried to implement the CDD approach in the search
for human tumour-speci¢c genes. This gene-hunting proce-
dure was inspired by the hypothesis that tumours might pro-
vide conditions for the expression of some genes that were not
expressed in any normal tissue [5]. An experimental approach
using combined preparations of mRNAs from several tissues
in saturation and subtractive hybridisation experiments [6] led
to the idea of subtracting all available tumour libraries against
all available normal libraries instead of pairwise comparisons
of each tumour and corresponding normal tissue.
Software instruments for CDD are available on NCBI
WWW sites such as UNIGENE and Cancer Genome Anat-
omy Project (CGAP). These tools have built-in limitations
that allow a researcher to operate only with pre-selected li-
braries. To overcome these limitations, we used the complete
set of human ESTs compiled in dbEST database as archived
£at-text ¢les and UNIGENE information concerning EST
clusterisation by perfect homology. By the time our search
was initiated (January 2001) the database included about
2.2U106 individual human cDNA sequences, each one tagged
with the description of a corresponding library. We developed
software for EST sorting on the basis of the cDNA tissue
source. It enabled us to ¢nd a set of genes highly expressed
in di¡erent tumours but not in normal tissues. The products
of such genes could serve as novel tumour markers and po-
tential targets for anti-tumour therapy.
2. Materials and methods
The digital di¡erential display (DDD) tool located on the UNIG-
ENE site was used to perform a model subtraction of libraries avail-
able on the same site (http://www.ncbi.nlm.nih.gov/UniGene/). The
human section of the dbEST database was obtained from the publicly
available NIH site (http://www.ncbi.nlm.nih.gov). EST clusters con-
taining cDNA-derived sequences of the same transcribed unit were
obtained from UNIGENE Build 129 which contained the following
data: EST descriptions including library identi¢ers as well as the nu-
cleotide sequences and indexes of all ESTs; ESTs grouped in about
90 000 clusters by internal algorithms developed by NCBI (see the
description at http://www.ncbi.nlm.nih.gov/UniGene/build.html);
and short descriptions of all libraries contributing to the database.
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These ¢les are available at (ftp://ncbi.nlm.nih.gov/repository/Uni-
Gene/). Any EST cluster linked to the descriptions of all incorporated
ESTs can be obtained using UNIGENE search engine (http://
www.ncbi.nlm.nih.gov/UniGene/).
We have developed a program called HSAnalyst to classify data
from original dbEST and UNIGENE databases in a table form. The
program is available at (http://pcn197.vigg.ru/programs/HSAnalyst.
exe). This program works with a supplementary database called Li-
braryRegistry which includes entries describing all human cDNA li-
braries classi¢ed by tissue source. This database contains a description
of libraries cross-referenced from di¡erent data sources including
dbEST, UNIGENE, CGAP (web-site available at NIH site), TIGR
(www.tigr.org) and Stratagene (www.stratagene.com). HSAnalyst
software is able to arrange EST data according to any given param-
eter, e.g. tissue type or the number of ESTs contained in a cluster.
Standard BLAST and FASTA program families were used to ana-
lyse the clusters of interest.
3. Results and discussion
We have carefully checked the descriptions of every library
we used to ensure that no libraries and, consequently, cDNA
clones were misclassi¢ed as ‘normal’ or ‘tumour’. Using avail-
able sources including UNIGENE, dbEST, TIGR, STRATA-
GENE, we have created the LibraryRegistry database con-
taining veri¢ed descriptions of all cDNA libraries. In this
database, libraries are classi¢ed as ‘tumour’ or ‘normal’ ac-
cording to their origin from tumour or normal tissues (cells).
Only well characterised libraries have been included in the
database. Libraries classi¢ed as ‘premalignant’, ‘non-cancer-
ous pathology’ and ‘immortalised cells’ have not been in-
cluded. Some libraries were rated as unde¢ned due to lack
of data or ambiguous information, and were not included.
This work has revealed many mistakes and data losses in
the original library descriptions. In total, 2681 libraries were
classi¢ed as ‘tumour’ and 1087 libraries as ‘normal’. The re-
sulting database contains 921 237 ‘tumour’ ESTs incorporated
in 56 241 clusters and 810 097 ‘normal’ ESTs incorporated in
53 762 clusters. 500 462 ESTs could not be classi¢ed as ‘tu-
mour’ or ‘normal’ libraries. The ‘normal’ subset was sub-
tracted from the ‘tumour’ in silico resulting in a group of
genes highly expressed in tumour, but not in normal tissues.
As a pilot phase of the experiment we chose all libraries
derived from tumour tissues, and performed the DDD proce-
dure versus the set of libraries derived from normal tissues.
This work was performed in January 2001. At this time the
DDD script operated with about 25% of total libraries from
the publicly available dbEST database. As a result, we have
obtained 41 clusters satisfying the following criteria: (1) each
cluster contains more than 10 ESTs belonging to a unique
cluster and (2) each cluster contains not more than one EST
from normal libraries. After the UNIGENE database was
rebuilt some clusters either changed dramatically or were to-
tally eliminated from the database due to new alignment re-
sults. Only 26 of 41 clusters preserved their structures, anchor-
ing ESTs and tumour EST prevalence after four successive
UniGene builds. These clusters were considered stable. How-
ever, 22 of 26 clusters ceased ¢tting the criterion (2) as they
pumped in normal library-derived ESTs during the subse-
quent growth of the dbEST database. All 26 stable clusters
were analysed by means of BLAST and FASTA tools and
compiled in Table 1. Only six of the 26 clusters listed in Table
1 correspond to human genes with well-established functions.
Most tumour-speci¢c clusters obtained by this method were
considered ‘new’ genes because they have not been found toT
ab
le
1
(c
on
ti
nu
ed
)
N
o.
U
ni
G
en
e
ID
P
ro
te
in
fu
nc
ti
on
(i
f
kn
ow
n)
or
cl
os
es
t
ho
m
ol
og
ue
P
ro
te
in
ho
m
ol
og
y,
%
/le
ng
th
,
aa
T
um
ou
r-
de
ri
ve
d
E
ST
s/
to
ta
l
E
ST
s
T
yp
es
of
tu
m
ou
rs
N
or
m
al
ti
ss
ue
s
21
H
s.
17
26
32
E
ST
s
17
/1
8
br
ea
st
ca
rc
in
om
a,
ol
ig
od
en
dr
og
lio
m
a,
ov
ar
ia
n
ca
rc
in
om
a
no
rm
al
bo
ne
m
ar
ro
w
22
H
s.
17
51
90
E
ST
s
35
/3
9
br
ea
st
,
lu
ng
an
d
ov
ar
ia
n
ca
rc
in
om
a,
ol
ig
od
en
dr
og
lio
m
a
br
ea
st
ep
it
he
liu
m
23
H
s.
13
31
07
E
ST
s
20
/2
0
ov
ar
ia
n
an
d
lu
ng
ca
rc
in
om
as
,
ol
ig
od
en
dr
og
lio
m
a
24
H
s.
13
32
96
E
ST
s
18
/1
8
ov
ar
ia
n
an
d
lu
ng
ca
rc
in
om
as
25
H
s.
14
54
92
E
ST
s
16
/1
6
ov
ar
ia
n
an
d
lu
ng
ca
rc
in
om
as
26
H
s.
18
16
24
E
ST
s
78
/7
8
ov
ar
ia
n
an
d
lu
ng
ca
rc
in
om
as
A
M
L
,
ac
ut
e
m
ye
lo
ge
no
us
le
uk
ae
m
ia
;
C
L
L
,
ch
ro
ni
c
ly
m
ph
oc
yt
ic
le
uk
ae
m
ia
;
C
M
L
,
ch
ro
ni
c
m
ye
lo
ge
no
us
le
uk
ae
m
ia
;
H
N
C
C
S,
he
ad
an
d
ne
ck
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a
;
P
N
E
T
,
pe
ri
ph
er
al
pr
im
i-
ti
ve
ne
ur
oe
ct
od
er
m
al
tu
m
ou
r;
SC
C
,
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a.
FEBS 25420 5-11-01
A.V. Baranova et al./FEBS Letters 508 (2001) 143^148 145
have any de¢ned function in the human organism. Eight of
the 20 remaining EST clusters represent genes displaying a
homology to known eucaryotic proteins, and 12 represent
unknown expressed sequences.
A program named HSAnalyst was developed to conduct
global analysis of cluster data. For complete CDD analysis
we used the LibraryRegistry database consisting of about
4000 library descriptions (this number is continually increas-
ing with the addition of new entries). An algorithm executed
by the program consists of two major steps: (1) for each
cluster the number of ESTs is retrieved from the cluster de-
scription and (2) the number of ESTs from the ‘tumour’
cDNA libraries is counted according to the LibraryRegistry
database. The whole range of possible EST numbers is dis-
sected into sub-ranges. HSAnalyst makes it possible to ar-
range sub-ranges exponentially (sub-ranges with exponents
1^2, 3^4, 5^8, 9^16, etc.) or linearly (sub-ranges with factors
1^10, 11^20, 21^30, etc.). Simultaneously, the ratio cancer
ESTs/all ESTs is calculated for each cluster, and those which
exceed the user-de¢ned bottom threshold value are listed in
the output ¢le. To be sure that we found ‘true’ tumour-speci¢c
clusters not generated by chance among the total number of
the EST clusters (more than 90 000 units) we calculated the
theoretical number of ‘tumour’ clusters for every sub-range.
The underlying model was the binomial distribution with the
mean value of ‘cancer/all’ ratio that could be de¢ned by a user
(0^100%). The number of clusters that exceeded threshold
value was calculated.
HSAnalyst output data describing two sets of clusters con-
taining more than 90 and 100% of tumour-related ESTs are
shown in Table 2. For each range of cluster sizes, ‘cancer-
related’ ESTs content, the number of clusters that comply
with the input conditions and the expected number of such
clusters are calculated. For the current database, the mean
content of ‘cancer-related’ ESTs is about 48%. Table 2 illus-
trates that tumour-speci¢c clusters are not accidental but rep-
resent a natural phenomenon. The results found by HSAna-
lyst agree with the data presented in Table 1: all 26 clusters
enlisted in Table 1 remain constant during UniGene database
growth. All of them are within the range of 17^128 by the
number of ESTs included in a cluster (counted with a thresh-
old s 90%). Twenty-one clusters falling in the range of 17^
128 contain only tumour-derived ESTs and ful¢l the 100%
threshold. Four of them coincide with strictly tumour-speci¢c
stable clusters found by DDD search, presented in Table 1
(NN 23^26). Seventeen extra clusters found during the global
analysis of cluster data and representing exclusively tumour-
derived mRNAs found by the HSAnalyst tool are presented in
Table 3.
All genes or gene fragments presented in Tables 1 and 3
have displayed high expression level in tumours and signi¢-
cantly lower expression level in normal tissues. Both Tables 1
and 3 contain clusters (genes) that have high similarity or
signi¢cant homology to known proteins and simultaneously
have a high content of tumour ESTs. Table 1 includes two
genes which encode proteins involved in cell contacts (liver^
intestine cadherin (LI) and keratin 16, mutated in focal non-
epidermolytic palmoplantar keratoderma), C1 complement-re-
lated factor, homeo box protein 1 belonging to H6 family,
and cytosolic branched chain aminotransferase 1. Among
genes overexpressed in tumour tissues containing open read-
ing frames with signi¢cant homologies to the known proteins,
the most interesting are those related to proteins involved in
carcinogenesis. They include a close homologue of an onco-
genic protein OCIM (90% of 344 amino acids) which plays a
role in multiple myeloma development; a homologue of
mouse growth di¡erentiation factor 3 (84% of 96 amino
acids); and a protein with weak homology to IQGA human
RAS GTPase-activating-like protein IQGAP1. Possible in-
volvement of these genes in human cancer development war-
rants further investigation.
The most interesting clusters were represented by ESTs
found exclusively in the tumour-derived libraries. Four tu-
mour-speci¢c clusters are represented in Table 1 (NN 23^26)
and 17 more in Table 3. The striking feature of the analysed
tumour-speci¢c clusters is their frequent occurrence in libra-
ries from colon carcinomas (Hs.560, Hs.1085, Hs.239891) or
lung and ovarian carcinomas (Hs.145340, Hs.145509,
Hs.181624, Hs.293429, Hs.133107, Hs.133296, Hs.145492,
Hs.181624). Interestingly, all three colon-speci¢c EST clusters
Table 2
Tumour-related clusters at di¡erent ranges
Range EST number Tumour-speci¢c
EST (%)
Number of tumour-related clusters at threshold (%)a
entries clusters s 90% 100%
observed expected observed expected
1^2 59 111 44 373 42 18 342 23 073 18 342 23 073
3^4 45 400 13 401 35 1880 1884 1880 1884
5^8 53 569 8742 37 567 279 567 172
9^16 63 421 5407 39 168 5 99 4
17^32 83 968 3607 41 45 0 17 0
33^64 176 845 3762 43 16 0 2 0
65^128 349 008 3790 45 10 0 2 0
129^256 460 493 2588 47 8 0 0 0
257^512 339 482 975 50 3 NAb 0 NA
513^1024 208 171 303 53 1 NA 0 NA
1025^2048 130 524 96 57 0 NA 0 NA
2049^4096 95 180 36 60 0 NA 0 NA
4097^8192 49 804 10 66 0 NA 0 NA
8193^16 384 14 725 1 67 0 NA 0 NA
The cases where the calculated number of clusters is less than one are shown in bold.
aExpressed as the persentage of tumour-speci¢c EST in the clusters.
bNA, not applicable. The ranges over 257 were not computed due to the lack of signi¢cant digits.
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obtained by our analysis represent the known genes encoding
apolipoprotein B mRNA-editing protein APOBEC1, guany-
late cyclase 2C and G protein-coupled receptor 35. Both
APOBEC1 and guanylate cyclase 2C mRNAs have been
shown to be overexpressed in colon carcinomas [7,8]. More-
over, the high-level expression of APOBEC1 in transgenic
mice and rabbit liver causes liver dysplasia and hepatocellular
carcinomas [9]. mRNA encoding guanylate cyclase 2C ap-
pears to be a relatively speci¢c marker for the presence of
metastatic colonic carcinoma cells in normal tissues including
peripheral blood [8]. In our opinion, the gene encoding G
protein-coupled receptor 35 deserves attention as a putative
marker of colon cancer possibly involved in the progression of
this important disease.
EST clusters from lung and ovarian carcinoma libraries
may also represent potential tumour markers. These clusters
do not contain any homologies to the known proteins and
open reading frames easily recognised. They may be consid-
ered evidence in favour of the expression of newly evolved
DNA sequences in tumour cells [5] or as a manifestation of
‘background’ or ‘illegitimate’ gene expression [10,11] which
may be enhanced in tumour cells due to dysregulation of
the house-keeping processes.
Di¡erentially expressed EST clusters (genes) can be useful
as tumour markers and prognostic indicators and can be suit-
able targets for various therapeutic interventions. We probed
a subset of EST clusters presented in Table 1 (six out of 26)
and Table 3 (¢ve out of 17) by con¢rmatory polymerase chain
reaction experiments on Clontech multiple tissues cDNA
(MTC) panels. The results are reassuring as mRNA corre-
sponding to the probed clusters Hs.133294, Hs.279805,
Hs.196073, Hs.154173, Hs.145340 and Hs.67624 showed ex-
pression in di¡erent tumours but not in normal tissues in-
cluded in MTC panels (data not shown). This con¢rms the
validity of the CDD procedure applied in this article.
Patent application (disclosed) ¢led.
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